About Renalys
Renalys is a company based in Chuo (Japan) founded in 2023 by Takeshi Takahashi and BT Slingsby was acquired by Chugai Pharmaceutical in October 2025.. Renalys has raised $38.2 million across 1 funding round from investors including Chugai Pharmaceutical, Catalys Pacific and SR One. Renalys operates in a competitive market with competitors including Calliditas Therapeutics, Enyo Pharma, Unicycive, Akebia Therapeutics and Alebund, among others.
- Headquarter Chuo, Japan
- Founders Takeshi Takahashi, BT Slingsby
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$38.2 M (USD)
in 1 rounds
-
Latest Funding Round
$38.2 M (USD), Series A
Jul 17, 2024
-
Investors
Chugai Pharmaceutical
& 6 more
-
Employee Count
Employee Count
-
Acquired by
Chugai Pharmaceutical
(Oct 24, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Renalys
Renalys has successfully raised a total of $38.2M through 1 strategic funding round. The most recent funding activity was a Series A round of $38.2 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $38.2M
-
First Round
First Round
(17 Jul 2024)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2024 | Amount | Series A - Renalys | Valuation | Catalys Pacific , SR One |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Renalys
Renalys has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Chugai Pharmaceutical, Catalys Pacific and SR One. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A biotechnology venture capital firm investing in innovative science.
|
Founded Year | Domain | Location | |
|
VC firm investing in Japan and the US
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Renalys
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Renalys
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Renalys Comparisons
Competitors of Renalys
Renalys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Calliditas Therapeutics, Enyo Pharma, Unicycive, Akebia Therapeutics and Alebund, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of small molecule based drug for inflammatory kidney disease
|
|
| domain | founded_year | HQ Location |
Therapeutics are developed for diseases with impaired kidney function.
|
|
| domain | founded_year | HQ Location |
Small molecule therapies for kidney diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for kidney disease treatment are developed by Akebia Therapeutics.
|
|
| domain | founded_year | HQ Location |
Therapeutics for various kidney diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for autoimmune diseases are developed by Aurinia Pharmaceuticals.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Renalys
Frequently Asked Questions about Renalys
When was Renalys founded?
Renalys was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Where is Renalys located?
Renalys is headquartered in Chuo, Japan. It is registered at Chuo, Yamanashi Prefecture, Japan.
Who is the current CEO of Renalys?
BT Slingsby is the current CEO of Renalys. They have also founded this company.
Is Renalys a funded company?
Renalys is a funded company, having raised a total of $38.2M across 1 funding round to date. The company's 1st funding round was a Series A of $38.2M, raised on Jul 17, 2024.
What does Renalys do?
Renalys was established in 2023 in Chuo City, Japan, within the biotechnology sector. Focus is placed on developing therapeutics for renal diseases. Sparsentan, an oral dual endothelin angiotensin receptor antagonist, has been introduced for treating IgA nephropathy. Operations center on advancing treatments for kidney-related conditions, with co-founders Takeshi Takahashi and BT Slingsby leading efforts in this specialized field.
Who are the top competitors of Renalys?
Renalys's top competitors include Calliditas Therapeutics, Enyo Pharma and Akebia Therapeutics.
Who are Renalys's investors?
Renalys has 7 investors. Key investors include Chugai Pharmaceutical, Catalys Pacific, SR One, JP Investment, and Sumitomo Mitsui Trust Bank.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.